The abstract is read at the publisher; the summary is JClub's.
NAD+ availability is linked to Influenza A virus replication, and lowering NAD+ with NAMPT inhibitors or 6-aminonicotinamide suppresses viral growth in vitro and ex vivo.
- Why it matters: Annual vaccine updates and early timing requirements for antivirals make it critical to understand IAV-linked metabolic changes that could be targeted to promote clearance and recovery.
- What they did: The study measured intracellular NAD and used NAMPT inhibitors or 6-aminonicotinamide to deplete NAD, then combined infected murine organotypic lung cultures with untargeted metabolomics and spatial transcriptomics.
- The result: IAV infection in mOLCs decreased NAD+ while PARPs were upregulated, and inhibiting mono-ADP-ribosyl transferase activity of PARPs restricted infection ex vivo, supporting NAMPT and PARP mono-ART as antiviral targets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.